The continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer offers a survival benefit.
about
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)Targeted therapies in colorectal cancer-an integrative view by PPPMDifferences in survival for patients with metastatic colorectal cancer by lines of treatment received and stage at original diagnosis.
P2860
The continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer offers a survival benefit.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
The continuation of bevacizuma ...... cer offers a survival benefit.
@en
The continuation of bevacizuma ...... cer offers a survival benefit.
@nl
type
label
The continuation of bevacizuma ...... cer offers a survival benefit.
@en
The continuation of bevacizuma ...... cer offers a survival benefit.
@nl
prefLabel
The continuation of bevacizuma ...... cer offers a survival benefit.
@en
The continuation of bevacizuma ...... cer offers a survival benefit.
@nl
P2093
P356
P1476
The continuation of bevacizuma ...... cer offers a survival benefit.
@en
P2093
Andriani Tsiakou
Georgios F Samelis
Konstantinos A Ekmektzoglou
Manousos Konstadoulakis
P304
P356
10.5754/HGE11179
P577
2011-11-01T00:00:00Z